tPA regulates pulmonary vascular activity through NMDA receptors

Taher Nassar, Khalil Bdeir, Serge Yarovoi, Rami Abu Fanne, Juan Carlos Murciano, Steven Idell, Timothy Craig Allen, Douglas B. Cines, Abd Al Roof Higazi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Tissue-type plasminogen activator (tPA) is a potent fibrinolytic enzyme used to treat acute coronary artery obstruction. However, tPA has shown limited utility in other disorders caused by thrombotic vascular occlusion, such as pulmonary embolism. We found that tPA caused dose-dependent effects on the contractility of pulmonary arterial rings that may affect its effectiveness as a thrombolytic agent. At low concentrations (1 nM), tPA stimulated pulmonary vascular contraction in response to phenylephrine, whereas at higher concentrations (20 nM) tPA inhibited pulmonary arterial contractility and promoted pulmonary vascular permeability through an interaction between its "docking site" and N-methyl d-aspartate receptor type 1 (NMDA-R1) expressed by pulmonary arteries. A hexapeptide derived from plasminogen activator inhibitor type 1 that blocked the docking site of tPA, but not its catalytic activity, inhibited its interaction with NMDA-R1, abolished inhibition of pulmonary artery contractility, attenuated vascular permeability, and facilitated fibrinolysis in a murine model of pulmonary embolism. Similar outcomes were seen using a tPA variant that lacks the docking site but retains catalytic activity. These data suggest that it is feasible to attenuate the deleterious extrafibrinolytic effects of tPA and improve its benefit:risk profile in the management of pulmonary embolism.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume301
Issue number3
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Plasminogen Activators
N-Methyl-D-Aspartate Receptors
Blood Vessels
Lung
Pulmonary Embolism
Capillary Permeability
Pulmonary Artery
Fibrinolytic Agents
Plasminogen Activator Inhibitor 1
Phenylephrine
Fibrinolysis
Tissue Plasminogen Activator
Catalytic Domain
Coronary Vessels
Enzymes

Keywords

  • Fibrinolytic enzymes
  • N-methyl-D-aspartate
  • Plasminogen activators
  • Pulmonary emboli
  • Tissue-type plasminogen activator

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology
  • Physiology

Cite this

Nassar, T., Bdeir, K., Yarovoi, S., Fanne, R. A., Murciano, J. C., Idell, S., ... Higazi, A. A. R. (2011). tPA regulates pulmonary vascular activity through NMDA receptors. American Journal of Physiology - Lung Cellular and Molecular Physiology, 301(3). https://doi.org/10.1152/ajplung.00429.2010

tPA regulates pulmonary vascular activity through NMDA receptors. / Nassar, Taher; Bdeir, Khalil; Yarovoi, Serge; Fanne, Rami Abu; Murciano, Juan Carlos; Idell, Steven; Allen, Timothy Craig; Cines, Douglas B.; Higazi, Abd Al Roof.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 301, No. 3, 09.2011.

Research output: Contribution to journalArticle

Nassar, T, Bdeir, K, Yarovoi, S, Fanne, RA, Murciano, JC, Idell, S, Allen, TC, Cines, DB & Higazi, AAR 2011, 'tPA regulates pulmonary vascular activity through NMDA receptors', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 301, no. 3. https://doi.org/10.1152/ajplung.00429.2010
Nassar, Taher ; Bdeir, Khalil ; Yarovoi, Serge ; Fanne, Rami Abu ; Murciano, Juan Carlos ; Idell, Steven ; Allen, Timothy Craig ; Cines, Douglas B. ; Higazi, Abd Al Roof. / tPA regulates pulmonary vascular activity through NMDA receptors. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2011 ; Vol. 301, No. 3.
@article{f674007a097d4932b3a34d04d4474dda,
title = "tPA regulates pulmonary vascular activity through NMDA receptors",
abstract = "Tissue-type plasminogen activator (tPA) is a potent fibrinolytic enzyme used to treat acute coronary artery obstruction. However, tPA has shown limited utility in other disorders caused by thrombotic vascular occlusion, such as pulmonary embolism. We found that tPA caused dose-dependent effects on the contractility of pulmonary arterial rings that may affect its effectiveness as a thrombolytic agent. At low concentrations (1 nM), tPA stimulated pulmonary vascular contraction in response to phenylephrine, whereas at higher concentrations (20 nM) tPA inhibited pulmonary arterial contractility and promoted pulmonary vascular permeability through an interaction between its {"}docking site{"} and N-methyl d-aspartate receptor type 1 (NMDA-R1) expressed by pulmonary arteries. A hexapeptide derived from plasminogen activator inhibitor type 1 that blocked the docking site of tPA, but not its catalytic activity, inhibited its interaction with NMDA-R1, abolished inhibition of pulmonary artery contractility, attenuated vascular permeability, and facilitated fibrinolysis in a murine model of pulmonary embolism. Similar outcomes were seen using a tPA variant that lacks the docking site but retains catalytic activity. These data suggest that it is feasible to attenuate the deleterious extrafibrinolytic effects of tPA and improve its benefit:risk profile in the management of pulmonary embolism.",
keywords = "Fibrinolytic enzymes, N-methyl-D-aspartate, Plasminogen activators, Pulmonary emboli, Tissue-type plasminogen activator",
author = "Taher Nassar and Khalil Bdeir and Serge Yarovoi and Fanne, {Rami Abu} and Murciano, {Juan Carlos} and Steven Idell and Allen, {Timothy Craig} and Cines, {Douglas B.} and Higazi, {Abd Al Roof}",
year = "2011",
month = "9",
doi = "10.1152/ajplung.00429.2010",
language = "English (US)",
volume = "301",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - tPA regulates pulmonary vascular activity through NMDA receptors

AU - Nassar, Taher

AU - Bdeir, Khalil

AU - Yarovoi, Serge

AU - Fanne, Rami Abu

AU - Murciano, Juan Carlos

AU - Idell, Steven

AU - Allen, Timothy Craig

AU - Cines, Douglas B.

AU - Higazi, Abd Al Roof

PY - 2011/9

Y1 - 2011/9

N2 - Tissue-type plasminogen activator (tPA) is a potent fibrinolytic enzyme used to treat acute coronary artery obstruction. However, tPA has shown limited utility in other disorders caused by thrombotic vascular occlusion, such as pulmonary embolism. We found that tPA caused dose-dependent effects on the contractility of pulmonary arterial rings that may affect its effectiveness as a thrombolytic agent. At low concentrations (1 nM), tPA stimulated pulmonary vascular contraction in response to phenylephrine, whereas at higher concentrations (20 nM) tPA inhibited pulmonary arterial contractility and promoted pulmonary vascular permeability through an interaction between its "docking site" and N-methyl d-aspartate receptor type 1 (NMDA-R1) expressed by pulmonary arteries. A hexapeptide derived from plasminogen activator inhibitor type 1 that blocked the docking site of tPA, but not its catalytic activity, inhibited its interaction with NMDA-R1, abolished inhibition of pulmonary artery contractility, attenuated vascular permeability, and facilitated fibrinolysis in a murine model of pulmonary embolism. Similar outcomes were seen using a tPA variant that lacks the docking site but retains catalytic activity. These data suggest that it is feasible to attenuate the deleterious extrafibrinolytic effects of tPA and improve its benefit:risk profile in the management of pulmonary embolism.

AB - Tissue-type plasminogen activator (tPA) is a potent fibrinolytic enzyme used to treat acute coronary artery obstruction. However, tPA has shown limited utility in other disorders caused by thrombotic vascular occlusion, such as pulmonary embolism. We found that tPA caused dose-dependent effects on the contractility of pulmonary arterial rings that may affect its effectiveness as a thrombolytic agent. At low concentrations (1 nM), tPA stimulated pulmonary vascular contraction in response to phenylephrine, whereas at higher concentrations (20 nM) tPA inhibited pulmonary arterial contractility and promoted pulmonary vascular permeability through an interaction between its "docking site" and N-methyl d-aspartate receptor type 1 (NMDA-R1) expressed by pulmonary arteries. A hexapeptide derived from plasminogen activator inhibitor type 1 that blocked the docking site of tPA, but not its catalytic activity, inhibited its interaction with NMDA-R1, abolished inhibition of pulmonary artery contractility, attenuated vascular permeability, and facilitated fibrinolysis in a murine model of pulmonary embolism. Similar outcomes were seen using a tPA variant that lacks the docking site but retains catalytic activity. These data suggest that it is feasible to attenuate the deleterious extrafibrinolytic effects of tPA and improve its benefit:risk profile in the management of pulmonary embolism.

KW - Fibrinolytic enzymes

KW - N-methyl-D-aspartate

KW - Plasminogen activators

KW - Pulmonary emboli

KW - Tissue-type plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=80052355803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052355803&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00429.2010

DO - 10.1152/ajplung.00429.2010

M3 - Article

VL - 301

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 3

ER -